AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact

Antivirals

March 15, 2017 By antoxa

Antibodies against Ebola

Antibodies produced using the vivoXPRESS® biopharmaceutical manufacturing system have been shown to neutralize the Sudan strain of Ebola as well as antibodies produced using other systems, according to analyses performed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) with funding support and technical advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

Building upon the USAMRIID project, our team worked with University of New Mexico scientists to advance Ebola research and improve existing vaccines by inducing more effective immune responses to infection. The project employed the vivoXPRESS® system to express glycoproteins found on Filoviridae, the family of viruses that cause Ebola and Marburg disease, two severe and often fatal viral hemorrhagic fevers that afflict humans and non-human primates.

 

 

Filed Under: Products

Proprietary Technology

March 15, 2017 By antoxa

Fast, low-cost, versatile and scaleable production

AntoXa holds an exclusive licence to use PlantForm Corporation’s vivoXPRESS® biopharmaceutical manufacturing platform to produce countermeasures for ricin, sarin, soman and the Ebola Sudan virus, as well as other biodefense therapeutics. This tobacco-plant-based system makes it easier, faster and less expensive to produce high-quality biologic drugs for novel indications and new markets.

Key advantages of the vivoXPRESS® platform include:

  • rapid drug development and production timelines
  • high levels of drug expression
  • mammalian-type glycosylation (less risk of unwanted immune reactions)
  • reduced risk profiles versatility (for new product development)
  • unlimited scale-up capability (to respond quickly to increased demand), and
  • manufacturing costs as much as 90 per cent lower than those for mammalian cell technology systems.

Patented next-generation therapeutics

The AntoXa team continues to advance the vivoXPRESS® platform, which originated at the University of Guelph through the work of Dr. J. Christopher Hall. All relevant intellectual property is protected by seven families of patent filings, with three patents issued to date.

Our product pipeline includes innovator antibodies for treatment of ricin exposure as well as the Ebola virus (Sudan strain), and recombinant butyrylcholinesterase (BuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants.

Filed Under: About Us

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6

Latest News

AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy

August 17, 2021

DRDC-funded project aims to develop recombinant human ...
Read more >

AntoXa awarded federal government contract for anti-nerve agent enzyme

March 20, 2019

GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been ...
Read more >

Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The tobacco-plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2022 · AntoXa Corporation | Site by DigitalNomad.marketing and Curry Gunn & Associates